ArticleBioMed research international2015
B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma.
Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis.Oncotarget · 2017Pooled it
- Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis.Oncotarget · 2016Pooled it
- A CIC-related-epigenetic factors-based model associated with prediction, the tumor microenvironment and drug sensitivity in osteosarcoma.Scientific reports · 2024Article
- Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response.Experimental animals · 2021Article
- Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.Frontiers in immunology · 2021Review
- Immune checkpoint: The novel target for antitumor therapy.Genes & diseases · 2021Review
- Prediction of the treatment response in ovarian cancer: a ctDNA approach.Journal of ovarian research · 2020Review
- The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.Trends in pharmacological sciences · 2019Review
- Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma.PloS one · 2018Article
- B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways.Leukemia · 2017Article
- Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists.BMC cancer · 2017Article
- Article
- New B7 Family Checkpoints in Human Cancers.Molecular cancer therapeutics · 2017Review
- B7-H4 promotes tumor growth and metastatic progression in lung cancer by impacting cell proliferation and survival.Oncotarget · 2017Article
- The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.Immunological reviews · 2017Review
- Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.Oncoimmunology · 2016Article
- B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidences have demonstrated that B7-H4 is associated with tumor development and prognosis. However, the clinical significance of B7-H4 expression in human osteosarcoma (OS) remains unclear. The aim of present study was to examine the B7-H4 expression and to explore its contribution in OS. B7-H4 expression in OS tissues was examined by immunohistochemistry. Soluble B7-H4 (sB7-H4) levels in blood were examined by ELISA. The association of B7-H4 expression with clinicopathological factors or prognosis was statistically analyzed. Our findings demonstrated that B7-H4 expression in OS tissues was significantly higher than those in paired normal bone tissues (P < 0.001). sB7-H4 level in OS serum samples was significantly higher than that in healthy controls (P = 0.005). High B7-H4 expression in tissues and sB7-H4 level were both correlated with advanced tumor stage (P < 0.001, P = 0.017, resp.) and distant metastasis (P = 0.034, P = 0.021, resp.). Additionally, high B7-H4 expression or serum sB7-H4 levels were significantly related to poor overall survival (P = 0.028, P = 0.005, resp.). B7-H4 in tissues and serum samples were an independent factor for affecting the survival time of OS patients (P = 0.004, P = 0.041, resp.). Collectively, our data suggest that the evaluation of B7-H4 expression in tissues and blood is a useful tool for predicting the progression of osteosarcoma and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.